Investors flock to Lifespot as a telehealth play
Published 25-MAR-2020 13:01 P.M.
|
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Shares in Lifespot Health Limited (ASX: LSH) opened at 5 cents on Wednesday morning and went on to trade as high as 5.3 cents, representing a gain of about 140%.
This was in response to information that the company provided regarding its fully integrated temperature self-tracking and monitoring system.
Lifespot’s core expertise is in connecting medical diagnostic devices and digital medicine delivery systems via Bluetooth and Smart device APPs to its cloud based ISO13485 accredited proprietary BodyTel patient management system.
The company’s systems and applications are cloud and smartphone-based and easy to use.
Lifespot has responded to consumer demand, developing this technology for individuals and organisations while deploying Australian and international resources to further develop and complete the BodyTelTM APP and platform extension.
This incorporates temperature monitoring via the Bodytel platform and a branded Bluetooth thermometer.
The current Australian government guidelines for COVID-19 recommend ongoing self-monitoring of symptoms including fever, coughing, sore throat, fatigue and shortness of breath.
When checking for fever, most of the current digital thermometers in the marketplace only keep a short series of historical data which is not visually represented to enable easy tracking.
In addition, this data is not able to be aggregated to provide community, organisation or geographical reporting.
More specifically, individual consent has to be obtained in order to share such data into an aggregated data set.
US research suggests Lifespot is on a winner
Recent studies in the US have shown that smart thermometers can be a new source of information for flu surveillance and forecasting, allowing for more rapid and efficient disease management.
In countries like Singapore and Hong Kong it is believed their approach to ongoing self-tracking and community tracking has been a significant driver of the ability to reduce the impact of COVID-19.
Management noted that the COVID-19 at risk patients can be those with Cardiovascular Disease or Diabetes.
The Bodytel® System already has the capability to track blood sugar, ECG, blood pressure and weight via the existing Bluetooth connected devices.
Extending the platform to track fever via body temperature is a commercially low risk, yet logical extension to the platform and can currently address the large unmet need globally for this function arising from the COVID-19 pandemic.
From a broader perspective, Lifespot provides its diagnostic systems and medicine delivery platforms to healthcare enterprises for own branding white label contracts.
The company’s German based proprietary BodyTel system is based on modern and future-proof internet technology, utilising advanced technologies such as document-based databases and biological neural networks.
General Information Only
This material has been prepared by Marko Babusku (MB, “I” or “me”). Marko Babusku is an authorised representative (AR 001315790) of 62 Consulting Pty Limited (ABN 88 664 809 303) (AFSL 548573) (62C), and an employee of S3 Consortium Pty Ltd (trading as Stocksdigital).
This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by 62C, MB, Stocksdigital, any of their related body corporates or any other person. To the maximum extent possible, 62C, MB, Stocksdigital, their related body corporates or any other person do not accept any liability for any statement in this material
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
